uniQure Stock Falls 18% as FDA Unlikely to Approve AMT-130 Gene Therapy for Huntington's Disease.
ByAinvest
Thursday, Dec 4, 2025 8:35 am ET1min read
QURE--
uniQure NV's stock is falling 18% in pre-market trade after the company received final meeting minutes from the FDA regarding a pre-Biologics License Application meeting for its gene therapy, AMT-130, for Huntington's disease. The FDA stated that the submitted Phase I/II study data are unlikely to provide primary evidence for a BLA submission. uniQure plans to request a follow-up meeting with the FDA in Q1 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet